文献速递生殖医学

随机对照试验:首次IVF(含或不含ICSI)前子宫内膜搔刮的临床有效性与安全性

A randomised controlled trial to assess the clinical effectiveness and safety of the endometrial scratch procedure prior to first-time IVF, with or without ICSI.
PubMed 文献 · Hum Reprod · 2021-01-01

这项多中心随机对照试验纳入1048名首次接受IVF(含或不含ICSI)的女性,评估黄体中期子宫内膜搔刮(ES)与常规治疗相比的有效性和安全性。结果显示ES安全但未改善妊娠结局:活产率常规治疗组37.1%,ES组38.6%,未调整绝对差1.5%(95%CI -4.4%至7.4%,P=0.621)。推荐该人群不进行ES。

要点

  • 首次IVF前黄体中期ES未显著提高活产率。
  • ES组与常规治疗组不良事件相当,安全性可接受。
  • 不推荐首次IVF(含或不含ICSI)女性常规进行ES。

核心结论

  • 黄体中期子宫内膜搔刮在首次IVF(含或不含ICSI)前实施是安全的,但未显著改善妊娠结局,不推荐该人群进行ES。

研究设计与样本

  • 实用性、优效性、开放标签、多中心、平行组随机对照试验,纳入1048名18-37岁首次接受IVF(含或不含ICSI)的女性,从英国16家生育诊所招募,2016年7月至2019年10月进行。

主要发现

  • 活产率常规治疗组为37.1%(195/525),ES组为38.6%(202/523),未调整绝对差1.5%(95%CI -4.4%至7.4%,P=0.621)。
  • 次要结局无统计学差异,不良事件两组相当。
  • ES组86.6%(453/523)接受了ES操作;IVF(含或不含ICSI)在ES组和常规治疗组分别有94.1%(494/525)和95.0%(497/523)接受。

关键数值与推荐

  • 主要结局为取卵后10.5个月内完成妊娠24周后的活产。
  • 推荐首次IVF(含或不含ICSI)女性不进行子宫内膜搔刮。

临床怎么用

  • 对于首次接受IVF(含或不含ICSI)的女性,不应常规提供子宫内膜搔刮作为辅助治疗。

局限性

  • 对照组未进行假ES操作,但作者认为这不会影响结果,因为使用了客观的生育结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the clinical-effectiveness and safety of the endometrial scratch (ES) procedure compared to no ES, prior to usual first time in vitro fertilisation (IVF) treatment? SUMMARY ANSWER: ES was safe but did not improve pregnancy outcomes when performed in the mid-luteal phase prior to the first IVF cycle, with or without intracytoplasmic sperm injection (ICSI). WHAT IS KNOWN ALREADY: ES is an 'add-on' treatment that is available to women undergoing a first cycle of IVF, with or without ICSI, despite a lack of evidence to support its use. STUDY DESIGN, SIZE, DURATION: This pragmatic, superiority, open-label, multi-centre, parallel-group randomised controlled trial involving 1048 women assessed the clinical effectiveness and safety of the ES procedure prior to first time IVF, with or without ICSI, between July 2016 and October 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants aged 18-37 years undergoing their first cycle of IVF, with or without ICSI, were recruited from 16 UK fertility clinics and randomised (1:1) by a web-based system with restricted access rights that concealed allocation. Stratified block randomisation was used to allocate participants to TAU or ES in the mid-luteal phase followed by usual IVF with or without ICSI treatment. The primary outcome was live birth after completing 24 weeks gestation within 10.5 months of egg collection. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 1048 women randomised to TAU (n = 525) and ES (n = 523) were available for intention to treat analysis. In the ES group, 453 (86.6%) received the ES procedure. IVF, with or without ICSI, was received in 494 (94.1%) and 497 (95.0%) of ES and TAU participants respectively. Live birth rate was 37.1% (195/525) in the TAU and 38.6% (202/523) in the ES: an unadjusted absolute difference of 1.5% (95% CI -4.4% to 7.4%, P = 0.621). There were no statistical differences in secondary outcomes. Adverse events were comparable across groups. LIMITATIONS, REASONS FOR CAUTION: A sham ES procedure was not undertaken in the control group, however, we do not believe this would have influenced the results as objective fertility outcomes were used. WIDER IMPLICATIONS OF THE FINDINGS: This is the largest trial that is adequately powered to assess the impact of ES on women undergoing their first cycle of IVF. ES was safe, but did not significantly improve pregnancy outcomes when performed in the mid-luteal phase prior to the first IVF or ICSI cycle. We recommend that ES is not undertaken in this population. STUDY FUNDING/COMPETING INTEREST(S): Funded by the National Institute of Health Research. Stephen Walters is an National Institute for Health Research (NIHR) Senior Investigator (2018 to present) and was a member of the following during the project: National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Clinical Trials and Evaluation Committee (2011-2017), NIHR HTA Commissioning Strategy Group (2012 to 2017); NIHR Programme Grants for Applied Research Committee (2020 to present); NIHR Pre doctoral Fellowship Committee (2019 to present). Dr. Martins da Silva reports grants from AstraZeneca, during the conduct of the study; and is Associate editor of Human Reproduction and Editorial Board member of Reproduction and Fertility. Dr. Bhide reports grants from Bart's Charity and grants and non-financial support from Pharmasure Pharmaceuticals outside the submitted work. TRIAL REGISTRATION NUMBER: ISRCTN number: ISRCTN23800982. TRIAL REGISTRATION DATE: 31 May 2016. DATE OF FIRST PATIENT’S ENROLMENT: 04 July 2016.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Metwally M, Chatters R, Dimairo M, et al. A randomised controlled trial to assess the clinical effectiveness and safety of the endometrial scratch procedure prior to first-time IVF, with or without ICSI. Hum Reprod. 2021. PMID: 34050362. doi:10.1093/humrep/deab041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。